Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-12-16
2000-12-19
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3120
Patent
active
061628271
ABSTRACT:
The amino acid glycine in an administered amount of above 0.4 g/Kg/day is used for treating symptoms of psychosis and of schizophrenia.
REFERENCES:
patent: 4904681 (1990-02-01), Cordi et al.
patent: 5068412 (1991-11-01), Ohfune et al.
patent: 5086072 (1992-02-01), Trullas et al.
patent: 5179085 (1993-01-01), Bigge et al.
patent: 5187171 (1993-02-01), Cordi et al.
patent: 5260324 (1993-11-01), Cordi et al.
patent: 5428069 (1995-06-01), Skolnick et al.
patent: 5656608 (1997-08-01), Schneider et al.
patent: 5837730 (1998-11-01), Javitt et al.
patent: 5854286 (1998-12-01), Javitt et al.
Andreasen N (1989): The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 155 (suppl. 7):49-52.
Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin SG (1990): An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics J Clin Psychopharmacol 10:71-72.
D'Souza DC, Morrissey K, Abi-Saab D, Damon D, Gil R, Bennett A, Krystal JH (1995): Intravenous glycine and oral D-cycloserine effects on CSF amino acids, plasma hormones, and behavior in healthy humans: Implications for schizophrenia. Schiz Res 15:147, 1995.
Javitt DC and Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
Johnson JW. Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:529-31, 1987.
Kay SR, Fiszbein, Opler LA (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13:261-276.
Leiderman Eduardo, Zylberman Ilana, Zukin Stephen R, Cooper Thoms B, Javitt Daniel C. (1996): Preliminary Investigation of High-Dose Oral Glycine on Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial. Biol Psychiatry 39:213-215.
Potkin SG, Costa Roy S, Sramek J, Jin Y, Gulasekaram B (1992): Glycine in the treatment of schizophrenia--theory and preliminary results, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press.
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989): Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12:416-24.
Waziri R (1989): Glycine therapy of schizophrenia. Biol Psychiatry 1988, 23:210-211 (letter).
M. Nilsson, et al., "Glycine and D-serine decrease MK-801-induced hyperactivity inmice" Journal of Neural Transmission (1997) 104: 1195-1205.
John P. Kaltenbach, et al., "Compounds Protective againsht Renal Tubular necrosis Induced by D-Serine and D-2,3-Diaminoproplonic Acid in the Rat.sup.1 "Experimental and Molecular Pathology 27,225-234 (1982).
Frank A. Carone, et al., "Urinary Loss of Glucose, Phosphate, and Protein by Diffusion into Proximal Straight Tubules Injured by D-Serine and Maleic Acid" Laboratory Investigation, vol. 52, No. 6, pg. 605, 1985.
Katsunobu Takahashi, et al., "In Vivo Evidence for the Link Between L-and D-Serine Metabolism in Rat Cerebral Cortex." Journal of Neurochemistry, vol., 69, No. 3, 1997.
Taka-aki Matsui, et al., "Functional Comparison of D-Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration" Journal of Neurochemistry Vo. 65, No. 1, 1995.
Guochuan Tsai, et al., "D-Serine Added to Antipsychotics for the Treatment of Schizophrenia" Society of Biological Psychiatry 1998, vol. 44 pg. 1081-1089.
Toth Eugene, Weiss Benjamine, Banay-Schwartz Miriam, Lajtha Abel (1986): Effect of Glycine Derivatives on Behavioral Changes induced by 3-Mercaptopropionic Acid or Phencyclidine in Mice 11:1-8.
Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex . . . evidence for the glutamate hypothesis, Biol. Psychiatry 35:84-95.
Kretschmer BD, Schmidt WJ (1992), Glycine agonists in the treatmen tof schizophrenia? Clin Neuropharmacol, 15:157-159.
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry, 52:998-1007.
Rosse Rb, Schwartz BL, Davis RE, Deutsch SI (1991), An NMDA intervention strategy in schizophrenia with "low dose" milacemide, Clin Neuropharmacol, 14:268-272.
Rosse RB, Fay.dbd.McCarthy M, Kendrick K, Davis RE, Deutsch SI (1996), D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia, Clin Neuropharmaol, 19:444-50.
Waziri R (1996), Glycine therapy of schizophrenia: some caveats, Biol Psyciatry, 39:115-6.
Wood PL (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10.
Toth et al. (1982): Elevation of Cerebral Levels of Nonessential Amino Acids in vivo by Administration of Large Doses, Neurochemical Research, 6, (12).
Javitt Daniel
MacMillan Keith D.
LandOfFree
Treatment of negative and cognitive symptoms of schizophrenia wi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of negative and cognitive symptoms of schizophrenia wi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of negative and cognitive symptoms of schizophrenia wi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-271685